Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 3Endometrial Neoplasms 2Endometrial Hyperplasia 2Ovarian Neoplasms 1Kidney Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Glioblastoma 1Cardiovascular Diseases 1Cardiotoxicity 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

Echocardiography 4Electrocardiography 2sulforaphane 1schizandrin 1sacubitril and valsartan sodium hydrate drug combination 1pegfilgrastim 1nicotinamide-beta-riboside 1fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1empagliflozin 1Watchful Waiting 1Vincristine 1Tablets 1Rituximab 1Proton Therapy 1Proteins 1Prednisolone 1Observation 1Medical History Taking 1Lenalidomide 1Laser-Doppler Flowmetry 1Exercise 1Environmental Biomarkers 1Echocardiography, Stress 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Clinical Laboratory Techniques 1Chemoradiotherapy 1Carvedilol 1Blood Pressure Determination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cardiotoxicity × Atorvastatin × Clear all
NCT05559164 2025-11-14

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Rutgers, The State University of New Jersey

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡